- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Newron Pharmaceuticals SpA (NWRN)
The Newron Pharmaceuticals share price today is 7.97, view SIX NWRN stock exchange data. Track the latest Newron Pharmaceuticals share price with real-time updates on NWRN stock performance including market cap, day range, 52-week range and dividend yield. Access NWRN charts, earnings dates and analyst estimates to support your investment decisions.
7.97
+0.38(+5.01%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.55
8.21
52 wk Range
5.72
31.85
NWRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.558.21
52 wk Range
5.7231.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NWRN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
43.18
Upside
+441.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Newron meets with FDA over US trial enrollment hold- Investing.com
- Newron meets with FDA over US trial enrollment hold
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 43.18
(+441.81% Upside)
Earnings
Latest Release
16-09-2025
EPS / Forecast
-- / -0.50
Revenue / Forecast
11.9M / --
Compare NWRN to Peers and Sector
Metrics to compare | NWRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNWRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.0x | −4.8x | −0.3x | |
PEG Ratio | 0.03 | −0.09 | 0.00 | |
Price/Book | −15.1x | 1.5x | 2.6x | |
Price / LTM Sales | 17.0x | 11.8x | 3.0x | |
Upside (Analyst Target) | - | 150.0% | 59.8% | |
Fair Value Upside | Unlock | 7.0% | 7.1% | Unlock |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Newron Pharmaceuticals (NWRN) Share Price Today?
The Newron Pharmaceuticals share price today is 7.97.
What is the current Newron Pharmaceuticals (NWRN) share price and day range?
As of 12-10-2026, the Newron Pharmaceuticals share price is 7.97, with a previous close of 7.59. The share price has ranged from 7.55 to 8.21 today, while the 52-week range spans from 5.72 to 31.85.
What Is the Newron Pharmaceuticals Market Cap?
As of today, Newron Pharmaceuticals market cap is 171.40M.
What Is the Newron Pharmaceuticals (NWRN) Share Price Target?
The average 12-month share price target for Newron Pharmaceuticals is 43.18, with a high estimate of 72.80610346 and a low estimate of 18.94957201. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +441.81% Upside potential.
What Is Newron Pharmaceuticals's Earnings Per Share (TTM)?
The Newron Pharmaceuticals EPS (TTM) is -1.46.
From a Technical Analysis Perspective, Is NWRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Newron Pharmaceuticals Trade On?
Newron Pharmaceuticals is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for Newron Pharmaceuticals?
The stock symbol for Newron Pharmaceuticals is "NWRN."
How Many Times Has Newron Pharmaceuticals Stock Split?
Newron Pharmaceuticals has split 0 times.
How Many Employees Does Newron Pharmaceuticals Have?
Newron Pharmaceuticals has 27 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.